Doug Fambrough Moves from VC to CEO Role

Doug Fambrough has stepped down as a general partner with Oxford Bioscience Partners, in order to become CEO of Oxford portfolio company Dicerna Pharmaceuticals Inc. He will remain as a venture partner with Oxford. Dicerna is a Cambridge, Mass.-based RNA interference company that has raised $21.4 million in VC funding from Oxford, Abingworth Management and Skyline Ventures. He tells peHUB that Dicerna will likely seek between $25 million and $30 million in new VC funding during the second half of this year.

North AmericaUSHuman ResourcesBriefs